India, July 14 -- Corcept Therapeutics Incorporated (CORT), a commercial-stage biopharma company focused on cortisol modulation, has submitted a New Drug Application - NDA to the U.S. FDA for relacorilant in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer.
The NDA is supported by data from Corcept's Phase 3 ROSELLA and earlier Phase 2 trials, which showed that patients receiving relacorilant with nab-paclitaxel experienced improved progression-free and overall survival compared to those on nab-paclitaxel alone. The treatment was well-tolerated and did not increase the incidence or severity of adverse events relative to standard therapy, indicating a favorable safety profile.
CEO Joseph K. Belanoff stated tha...